Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Cancer Highlights | The Drug Target Atlas of Apoptopic Drugs in Oncology

The Drug Target Atlas of Apoptopic Drugs in Oncology

The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most.

Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.

First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology.

In the report, BioSeeker reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications. The highest degree of distinctiveness among apoptopic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.

The report by the numbers

* 250+ pages, with almost a hundred different tables. Includes more than 1,500 active links to related resources on the Internet

* 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer

* 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.

* 90 Unique drug target combinations of apoptopic drugs

* 452 protein-protein interactions among apoptopic drug targets

Extensive pathway analysis of drug targets

This report serves as a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Pages: 250+ February 2008
Table of Contents
Price: $3,800.00 / €2,542.20

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions